

Indices	Value	Pts	Chg (%)
SENSEX	48600.6	2314.8	5.00
NIFTY	14281.2	646.6	4.74
SGX NIFTY*	14469.5	111.0	0.77
DOW Jones	30211.9	229.3	0.76
S&P	3773.9	59.6	1.61
Nasdaq	13403.4	332.7	2.55
FTSE	6466.4	59.0	0.92
CAC	5461.7	62.5	1.16
DAX	13622.0	189.2	1.41
Shanghai Composite*	5460.3	42.7	0.79
Nikkei*	28339.4	248.3	0.88
Hang Seng*	29428.4	535.5	1.85

*As at 8.00 am

Most Active Call & Put			
Symbol	Strike Price	OI (000)	Chg (%)
NIFTY	15000CE	48452	24.2
NIFTY	13000PE	49122	59.1

Commodity	Price	Pts	Chg (%)
NYMEX Crude (USD)	54.2	0.6	1.1
Brent Crude (USD)	57.0	0.6	1.1
Gold (USD)	1864.4	0.5	0.0
Silver (USD)	28.76	-0.66	-2.25
Copper (USD)	356.4	1.8	0.51
Cotton (USD)	80.26	0.23	0.29

Currency	Value	Pts	Chg (%)
USD/Rupee	73.11	-0.01	-0.01
Euro/Rupee	88.37	0.16	0.18
Pound/Rupee	100.08	0.17	0.17
USD/Euro	1.21	0.00	0.17
Dollar Index	90.87	-0.11	-0.12

Indicators	Value	Pts	Chg (%)
CBOE VIX	30.2	-2.9	-8.6
India VIX	23.3	-2.0	-7.8

Indicators	Value	Bps chg
India 10-Yr Yield	6.06	11.1
US 10-Yr Yield	1.09	1.0

Trade Statistics	BSE	NSE	F & O
Turnover (INR Crs)	4292	84499	3853697
Advance (Nos)	27	45	NA
Declines (Nos)	3	5	NA
Unchanged	0	0	NA

Market Summary

The bulls on Dalal Street saluted the Union Budget presented by Finance Minister Nirmala Sitharaman for FY22, so much so, that they posted best ever Budget-day gains in absolute terms with BSE barometer Sensex rising 2,315 points to 48,601 while NSE Nifty added 647 points to end at 14,281. Looks like, the euphoria in the market is likely to continue even today with SGX Nifty ruling 75 points up at 14,435. While the market participants will continue to comb through the finer details of the Union Budget, global market mood, Q3 results and FII inflows will also sway the market sentiment.

In overnight session, US Stocks climbed as some of the world's largest technology companies rallied and several strategists said the recent explosion of speculative buying won't derail the bull market in equities. The Dow Jones Industrial Average rose 0.76% while Nasdaq Composite added 2.55%. The S&P 500, meanwhile, registered its biggest daily percentage gain since November 24 as it rose 1.61%.

Consequently, Asian stocks advanced with US futures on Tuesday morning amid receding concerns about volatile retail trading, progress on vaccinations and talks over U.S. stimulus. Topix index rose 0.8%, Australia's S&P/ASX 200 Index rose 1.3%, Kospi index gained 2.6% and Hang Seng Index climbed 1.6%.

That apart, foreign institutional investors (FIIs) turned net sellers in Indian markets after a five-day hiatus. FIIs net bought shares worth Rs 1,494.23 crore while domestic institutional investors net sold shares worth Rs 90.46 crore.

HDFC, Balrampur Chini Mills, Dixon Technologies, Escorts, IIFL Wealth Management and Tata Consumer Products are among 69 companies set to announce their quarterly earnings later today.

Macro News

India's Jan factory activity at 3-mth high, manufacturing PMI rises to 57.7

India's factory activity expanded at its strongest pace in three months in January, fuelled by a continued recovery in demand and output, according to a private survey which also showed firms cut jobs at the slowest pace in 10 months. The Nikkei Manufacturing Purchasing Managers' Index, compiled by IHS Markit, rose to 57.7 in January from December's 56.4, above the 50-level separating growth from contraction for the sixth straight month. Sub indexes tracking new orders and output rose to their highest since October, indicating strong growth in demand.

Subsidy bill nears Rs 6 trn in FY21 on extra free foodgrain distribution

The government's subsidies on food, fertilisers, LPG and kerosene are pegged at Rs 5.96 lakh crore in the current fiscal, over 2.5-fold jump from the initial budget estimates as the Centre distributed additional foodgrains free of cost to help poor mitigate the impact of COVID-19 pandemic. In February 2020 Budget, presented in the pre-COVID scare, the government had estimated the subsidy bill at Rs 2,27,794 crore. However, all the budget estimates, have undergone major revisions as the country imposed strict lockdown to check the spread of COVID-19. On Monday, Finance Minister Nirmala Sitharaman presented revised numbers of major subsidies.

Capital outlay should support a higher pace of GDP expansion in FY22

Budget 2021 speech was announcement-packed, prioritising health and infrastructure, and delivered to a large extent on the extraordinarily elevated expectations. Nevertheless, timely implementation of the myriad proposals holds the key for sustaining the incipient growth revival that is underway in H2 FY2021, and helping the economy attain a higher growth trajectory over the medium term.

Institutional Activity	Cash	
	01-Feb-21	29-Jan-21
FII (INR Crs)		
Buy	10168.32	11875.01
Sell	8674.09	17805.67
Net	1494.23	(5930.66)
DII (INR Crs)		
Buy	6603.46	7582.45
Sell	6693.92	5139.25
Net	(90.46)	2443.20

FII Derivative Statistics			
Particulars	Buy (INR Crs)	Sell (INR Crs)	OI (Nos)
INDEX FUTURES	6472.67	6477.73	117312
INDEX OPTIONS	247516.59	245045.78	713263
STOCK FUTURES	17412.20	17595.13	1142457
STOCK OPTIONS	10354.73	10550.17	89606
Total	281756.19	279668.81	

Gainers & Losers	Price	Chg (%)
Gainers (INR)		
INDUSINDBK	974.20	15.14
ICICIBANK	608.75	13.36
BAJAJFINSV	9740.00	11.66
SBIN	313.00	10.95
LT	1458.75	9.29
Losers (INR)		
UPL	535.80	-4.43
DRREDDY	4434.30	-3.66
CIPLA	805.95	-2.42
TECHM	947.95	-1.40
HINDUNILVR	2255.00	-0.39

Sectoral Performance	Value	Pts	Chg (%)
S&P BSE Small Cap	18353.32	365.12	2.03
S&P BSE Mid-Cap	18630.31	548.08	3.03
S&P BSE Auto	23058.65	930.96	4.21
S&P BSE BANKEX	37549.19	2886.68	8.33
S&P BSE Capital Goods	20549.70	1068.17	5.48
S&P BSE FMCG	12439.33	221.09	1.81
S&P BSE Healthcare	20683.18	54.47	0.26
S&P BSE IT	25116.30	295.61	1.19
S&P BSE Metals	11603.90	572.78	5.19
S&P Oil & Gas	14115.62	303.64	2.20

Key News

Lupin plans expansion, aims to enter Chinese market in the next one year

Mumbai-headquartered Lupin is firming up plans to enter the Chinese market in the next one year. Its peers Sun Pharmaceuticals and Dr Reddy's Laboratories (DRL) already have a presence in the dragon nation. Nilesh Gupta, managing director of Lupin, confirmed that the firm was keen to enter China. "In fact, last March, a management team was scheduled to visit China to explore prospects. This, however, could not happen due to the pandemic. We were planning to enter the market in 2021, but it got delayed due to the pandemic," Gupta said.

Maruti Suzuki reports 4.3% increase in total sales to 160,752 units in Jan

The country's largest car maker Maruti Suzuki India (MSI) on Monday reported a 4.3 per cent increase in total sales to 1,60,752 units in January. The company had sold 1,54,123 units in January last year, Maruti Suzuki India (MSI) said in a statement. Domestic sales rose 2.6 per cent to 1,48,307 units last month as against 1,44,499 units in January 2020, it added. Sales of mini cars, comprising Alto and S-Presso, declined 7.4 per cent to 1,02,088 units as compared with 1,10,225 in the same month last year.

45% spike in bike volumes drives TVS Motor two-wheeler sales up 34% in Jan

TVS Motor reported a 34 per cent growth in two-wheeler sales to 294,596 units in January 2021 from 220,439 units in January 2020. Domestic two-wheeler sales were up 26 per cent registering 205,216 units in January 2021 as against 163,007 units in January 2020. Motorcycle sales grew 45 per cent to 136,790 units in January 2021, from 94,367 units in January 2020. Scooter sales of the Company grew by 36 per cent registering 98,319 units in January 2021 as against 72,383 units in January 2020.

Adani Green arm commissions 100 MW solar power plant in Jalalabad

Adani Green Energy on Monday said that its arm ASE4PL has commissioned a 100 MW solar power project at Jalalabad in Uttar Pradesh. "ASE4PL (Adani Solar Energy Four Private Ltd), a subsidiary of Adani Green Energy Ltd (AGEL), commissioned 100 MW (2x50 MW) Solar Power Plants at Jalalabad in Shahjahanpur district and Sahaswan in Budaun district of Uttar Pradesh," a company statement said. It said, "Our team of experts made it possible to commission the plants almost 1 month ahead to their scheduled commissioning date."

Disinvestment of Air India, Pawan Hans to be completed in 2021-22: FM

Disinvestment of Air India and Pawan Hans would be completed in 2021-22, Finance Minister Nirmala Sitharaman said on Monday while presenting the Union Budget in which Rs 3,224 crore has been allocated to the Civil Aviation Ministry for the next fiscal year. Air India is currently undergoing disinvestment process. Multiple entities submitted their expression of interest (EOI) for the carrier in December. The government is likely to reveal the names of qualified bidders in the coming weeks.

Bharat Biotech hails Rs 35,000 cr budget allocation for Covid vaccination

Covaxin maker Bharat Biotech on Monday described as "far reaching" initiative the allocation of Rs 35,000 crore for COVID-19 vaccination in the Union Budget and said it would help the country become free of the viral disease. Dr. Reddys Laboratories Ltd said the budget was growth-oriented with a lot of positive interventions and with "something in it for everyone".



Analyst Certification of Independence: The analyst(s) for this report certifies that all the views expressed in this report accurately reflect his or her personal views about the subject company(ies) or issuers and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of SPA Securities Limited, and have no bearing whatsoever on any recommendation that they have given in the Research Report. Disclaimer and Disclosures as required under SEBI (Research Analyst) Regulations, 2014: SPA Securities Limited (hereinafter refer as SPA Securities) and its affiliates are engaged in investment banking, investment advisory, stock broking, institutional equities, Mutual Fund Distributor and insurance broking. SPA Securities is a SEBI registered securities broking Company having membership of NSE, BSE & MSEI for Equity, Future & Option, Currency Derivatives segment and Wholesale Debt Market. The Company is focused primarily on providing securities broking services to institutional clients and is empanelled as an approved securities broker with all the major Nationalised, Private and Co-operative banks, Corporate houses, Insurance Companies, Financial Institutions, Asset Management Companies and Provident Fund Trusts. Details of affiliates are available on our website i.e. www.spasecurities.com.

SPA Securities Limited is registered as a Research Analyst under SEBI (Research Analyst) Regulations, 2014. Vide SEBI Reg. No. INH00002615.

We hereby declare that our activities were neither suspended nor we have defaulted with any stock exchange authority with whom we are registered in the last five years. We have not been debarred from doing business by any Stock Exchange/SEBI or any other authorities, nor has our certificate of registration been cancelled by SEBI at any point of time.

General Disclosures: This Research Report (hereinafter called "report") has been prepared by SPA Securities and is meant for sole use by the recipient and not for circulation. This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, (as defined under section 2(h) of securities Contracts (Regulation) Act.1956, through SPA Securities nor any solicitation or offering of any investment/trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments.

This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by SPA Securities to be reliable, although its accuracy and completeness cannot be guaranteed. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. Any review, retransmission or any other use is prohibited.

The information, opinions, views expressed in this Research Report are those of the research analyst as at the date of this Research Report which are subject to change and do not represent to be an authority on the subject. While we would endeavour to update the information herein on a reasonable basis, we are under no obligation to update the information. Also, there may be regulatory, compliance or other reasons that prevent us from doing so. Hence all such information and opinions are subject to change without notice.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein.

This Research Report should be read and relied upon at the sole discretion and risk of the recipient. If you are dissatisfied with the contents of this complimentary Research Report or with the terms of this Disclaimer, your sole and exclusive remedy is to stop using this Research Report. Neither SPA Securities nor its affiliates or their respective directors, employees, agents or representatives shall be responsible or liable in any manner, directly or indirectly, for the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. SPA Securities may have issued other reports in the past that are inconsistent with and reach different conclusion from the information presented in this report.

SPA Securities, its affiliates and employees may, from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report.

The user should consult their own advisors to determine the merits and risks of investment and also read the Risk Disclosure Documents for Capital Markets and Derivative Segments as prescribed by Securities and Exchange Board of India before investing in the Indian Markets.

A graph of daily closing prices of securities is available at www.nseindia.com and <http://economictimes.indiatimes.com/markets/stocks/stock-quotes>. (Choose a company from the list on the browser and select the "three years" icon in the price chart).

Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject SPA Securities or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently sent or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published for any purposes without prior written approval of SPA Securities.

List of Associates as per SEBI (Research Analyst) Regulations, 2014

Statements on ownership and material conflicts of interest, compensation - SPA and Associates

Disclosure of interest statement	Yes/No
SPA Securities/its Affiliates/Analyst/his or her Relative financial interest in the company	No
SPA Securities/its Affiliates/Analyst/his or her Relative actual/beneficial ownership of more than 1% in subject company at the end of the month. Immediately preceding the date of the publication of the research report or date of public appearance.	No
Investment banking relationship with the company covered	No
Any other material conflict of interest at the time of publishing the research report	No
Receipt of compensation by SPA Securities or its Affiliated Companies from the subject company covered for in the last twelve months:	
<ul style="list-style-type: none"> Managing/co-managing public offering of securities Investment banking/merchant banking/brokerage services products or services other than those above in connection with research report 	No
Whether Research Analyst has served as an officer, director or employee of the subject company covered	No
Whether the Research Analyst or Research Entity has been engaged in market making activity of the Subject Company;	No

For statements on ownership and material conflicts of interest, compensation, etc. for individual Research Analyst(s), please refer to each specific research report.

SPA Securities Ltd: Mittal Court, A-Wing, 10th Floor, Nariman Point, Mumbai - 400 021, Tel. No. : +91-022-4289 5600, Fax: +91 (22) 2657 3708/9

SPA GLOBAL PRIVATE LIMITED
 Mutual Fund Advisor
 AMFI Reg. No. 90796

SPA SECURITIES LTD	SEBI REG. NOS.
NSE Cash	INZ000241036
NSE Future & Option	INZ000241036
NSE Currency Derivatives	INZ000241036
BSE Cash	INZ000241036
BSE Currency Derivatives	INZ000241036
MSEI Cash	INZ000241036
MSEI Future & Option	INZ000241036
MSEI Currency Derivatives	INZ000241036
Mutual Fund	ARN 77388
CDSL DP	IN-DP-CDSL-485-2008
NSDL DP	IN-DP-NSDL-316-2009
SEBI Research Analyst	INH100002615
Merchant Banker	INM000012740